PBM.US Psyence Biomedical Ltd. Common Shares

Healthcare Biotechnology USA Stocks
3.14 USD
Close of Nov 17, 2026
1.92 17.47
Market cap
USD 12.0M
P/E
-
P/B
0.71x
ROE
-40.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is PBM.US undervalued?

Graham number

The Graham number of Psyence Biomedical Ltd. Common Shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Psyence Biomedical Ltd. Common Shares fundamental analysis

No fundamental analysis for Psyence Biomedical Ltd. Common Shares yet.

Psyence Biomedical Ltd. Common Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Psyence Biomedical Ltd. Common Shares

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Full company profile